A key cancer treatment developed by Celltrion has become the first rituximab biosimilar to receive interchangeability status from the United States Food and Drug Administration (FDA), a designation expected to strengthen its position in one of the world’s most competitive drug markets. Celltrion said Wednesday that its blood cancer treatment Truxima (rituximab) has been granted interchangeability status by the FDA, marking the first time a rituximab biosimilar has received such recognition in the United States. The company said the designation allows Truxima to be substituted for its reference biologic without requiring a new prescription, under conditions permitted by U.S. law, and confirms no clinically meaningful differences in safety or effectiveness. The FDA decision also grants Truxima exclusivity tied to its status as the first interchangeable biosimilar in its class, according to the company. Truxima is approved in the United States for all adult indications held by the reference product, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis and m